Fewer than one in 10 patients that would benefit from GLP-1 drugs such as Wegovy are able to get them, caution the World Health Organization as it publishes its initial guidance on the medications.
Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for more widespread and fairer availability to GLP-1 medication.
Per projections, more than two billion are projected to be living with obesity by 2030 without intervention.
"Our latest guidelines acknowledges that obesity is a lifelong illness that can be treated with thorough and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are key obstacles to broad availability to the treatments that can assist patients in reducing substantial body mass, explains the organization.
Skinny Jab Shortage
Despite the present most favorable case, the supply of these medications might only reach approximately 100 million people – less than 10% of eligible patients, according to the WHO.
The guideline calls on governments and firms to increase access, through approaches including patent sharing.
A patent on the active ingredient – the primary ingredient of a leading brand – is scheduled to end in several countries in 2026.
How Weight-Loss Jabs Work
GLP-1 drugs mimick a natural hormone to slow digestion, reduce hunger and enhance feelings of fullness so individuals eat less.
Patients typically begin shedding pounds in the initial weeks of beginning the weekly injections.
Evidence indicates people may see weight return after a year of discontinuing the medication, as their typical food cravings return.
To be carrying excess weight increases your chance for developing health problems, like diabetes, heart disease, brain attack, and specific cancers.
Excess weight impacts people in every country and was associated with millions of fatalities worldwide in 2024, according to the health agency.
